Fintel reports that on October 4, 2023, RBC Capital reiterated coverage of Regenxbio (NASDAQ:RGNX) with a Sector Perform recommendation.
Analyst Price Forecast Suggests 155.14% Upside
As of August 31, 2023, the average one-year price target for Regenxbio is 42.10. The forecasts range from a low of 12.12 to a high of $68.25. The average price target represents an increase of 155.14% from its latest reported closing price of 16.50.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Regenxbio is 189MM, an increase of 94.78%. The projected annual non-GAAP EPS is -3.81.
What is the Fund Sentiment?
There are 422 funds or institutions reporting positions in Regenxbio. This is a decrease of 38 owner(s) or 8.26% in the last quarter. Average portfolio weight of all funds dedicated to RGNX is 0.13%, an increase of 16.73%. Total shares owned by institutions decreased in the last three months by 0.96% to 41,310K shares. 
The put/call ratio of RGNX is 0.47, indicating a bullish outlook.
What are Other Shareholders Doing?
Jpmorgan Chase holds 3,702K shares representing 8.42% ownership of the company. In it's prior filing, the firm reported owning 4,006K shares, representing a decrease of 8.21%. The firm increased its portfolio allocation in RGNX by 593.97% over the last quarter.
IJR - iShares Core S&P Small-Cap ETF holds 2,652K shares representing 6.03% ownership of the company. In it's prior filing, the firm reported owning 2,739K shares, representing a decrease of 3.30%. The firm decreased its portfolio allocation in RGNX by 0.90% over the last quarter.
Redmile Group holds 2,027K shares representing 4.61% ownership of the company. In it's prior filing, the firm reported owning 1,641K shares, representing an increase of 19.04%. The firm increased its portfolio allocation in RGNX by 15.50% over the last quarter.
XBI - SPDR(R) S&P(R) Biotech ETF holds 1,355K shares representing 3.08% ownership of the company. In it's prior filing, the firm reported owning 1,196K shares, representing an increase of 11.74%. The firm increased its portfolio allocation in RGNX by 19.21% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 1,239K shares representing 2.82% ownership of the company. In it's prior filing, the firm reported owning 1,189K shares, representing an increase of 4.08%. The firm increased its portfolio allocation in RGNX by 1.69% over the last quarter.
Regenxbio Background Information
(This description is provided by the company.)
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
